All 23 Healthcare posts we have indexed from venture capital blogs and newsletters, plus the highest-scoring pieces of the past year and the people who write about it most.
AI is reshaping drug discovery economics by improving success rates and reducing development time and cost, potentially enabling pharma companies to earn "valuation credit" like software businesses and spawning a wave of AI-native biotech startups building discovery platforms or their own therapeutics.
Analyzing 30 robotics companies, this data-driven breakdown shows $31B in annual robot revenue but a striking divergence: surgical robots (led by Intuitive Surgical) command 56% of market value despite being outpaced in revenue by industrial arms, while humanoid makers have minimal sales but massive investor valuations—raising the question of whether today's hype will convert to sustained revenue.
As AI capabilities approach AGI-level performance and costs plummet, cognitive labor and generic knowledge work become cheap; the author argues physical assets, energy, regulatory approval, and proprietary data on the physical world become the scarce, valuable bottlenecks—and outlines the Deep Tech Fund's investment thesis accordingly.
Fluent's investment thesis on global health: proven business models (AI primary care, D2C, home care delivery, practice software) working in one geography are being replicated across borders and sectors, with AI and localization as key multipliers.
Clinical AI is shifting from administrative tasks to diagnosis and treatment decisions, driven by consumer demand and physician shortages. Success requires navigating regulatory complexity, reimbursement uncertainty, and the autonomy curve—not just raw model performance.
Employer-sponsored health insurance is ripe for disruption as rising costs force employers to shop, AI reduces operational barriers, and consumers demand better experiences. Challenger health plans competing across underwriting, care navigation, and admin efficiency represent a generational replacement opportunity.
Healthcare AI faces the 'Oracle Problem': benchmarks cannot reliably measure model performance because clinical ground truth is subjective, data is proprietary, and evaluation metrics become marketing tools. Real-world outcomes—not test scores—must drive AI adoption in medicine.
GLP-1 drugs (semaglutide, tirzepatide) generated $71B in 2025—outearning OpenAI and Anthropic combined—while reaching under 2% of eligible patients globally. As new trials reveal benefits beyond obesity (addiction, kidney disease, cardiovascular), the addressable market and revenue potential expand dramatically.
Not Boring (6) · A16Z (6) · Vickram Pradhan (4) · Alex Lazarow (4) · SignalFire (3) · BIG by Matt Stoller (2) · Madrona Ventures (2) · 7wire Ventures (2) · Lerer Hippeau (1) · writing out loud (1)
Suggest a blog or newsletter for the SandHill index. We track the RSS feed and feature the best pieces in the weekly digest.
The latest theses & analyses from 800+ venture investors, curated into one email. Join 5,000+ investors, founders and LPs.